Plus, news about Eledon and Travere Therapeutics:
Lykos Therapeutics’ MDMA therapy gets an adcomm date: An FDA advisory committee is scheduled to meet June 4 to weigh the benefits and risks of the biotech’s NDA for its midomafetamine (MDMA) capsules in combination with psychological intervention for adults with post-traumatic stress disorder (PTSD). This will be the first adcomm meeting to review a new PTSD treatment in 25 years. — Ayisha Sharma
GSK supports BioVersys’ Series C extension: The CHF 12.3 million extension brings BioVersys’ total Series C proceeds to CHF 44.9 million, which is about $49 million. GSK also expanded its partnership with the Swiss biotech to advance alpibectir, its Phase 2a drug candidate for tuberculosis.— Ayisha Sharma
Eledon shares updated clinical data, $50M PIPE: The company is selling about 13.1 million shares at $2.37 each to support development of tegoprubart, a mid-stage treatment aimed at preventing rejected kidney transplantation. The candidate is also being tested to see if it can avert islet cell transplant rejection in type 1 diabetes patients. The financing was led by BVF Partners. — Jaimy Lee
Travere snags priority review to convert its IgAN drug to full approval: The drug, Filspari, received accelerated approval in early 2023, though it later missed the primary endpoint in a confirmatory study. The FDA is now set to decide whether to grant full approval to the treatment by Sept. 5. Travere’s stock $TVTX was up about 14% on Tuesday morning. — Jaimy Lee